粪乳铁蛋白预测溃疡性结肠炎预后的轨迹。

IF 12.2 1区 工程技术 Q1 ENGINEERING, INDUSTRIAL
Journal of Manufacturing Systems Pub Date : 2023-09-05 eCollection Date: 2023-09-01 DOI:10.1093/pcmedi/pbad022
Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang
{"title":"粪乳铁蛋白预测溃疡性结肠炎预后的轨迹。","authors":"Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang","doi":"10.1093/pcmedi/pbad022","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).</p><p><strong>Methods: </strong>This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (<i>n</i> = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (<i>n</i> = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.</p><p><strong>Results: </strong>The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were associated with prior exposure to anti-tumor necrosis factor agents and vedolizumab. Furthermore, the fecal lactoferrin trajectory was the most valuable predictor of endoscopic, clinical, and histological remission. Compared to the high/moderate-rapid decrease trajectory group, the moderate-slow decrease, high-slow decrease, and high-stable groups had adjusted odds ratios (95% confidence interval) of 0.38 (0.18, 0.78; <i>P </i>= 0.010), 0.47 (0.23, 0.93; <i>P </i>= 0.032), and 0.33 (0.17, 0.63; <i>P</i> = 0.001), respectively, of 1-year endoscopic remission. Patients with high/moderate-rapid decrease trajectories also had the highest likelihood of achieving clinical and histological remission. Finally, we developed a patient-stratification scheme based on fecal lactoferrin trajectories and concentrations. Patients with good, moderate, and poor prognoses in the scheme had a distinct probability of achieving 1-year endoscopic remission (52.7%, 30.9%, and 12.8%, respectively).</p><p><strong>Conclusions: </strong>The trajectory of fecal lactoferrin is a valuable prognostic factor for 1-year remission in UC.</p>","PeriodicalId":16227,"journal":{"name":"Journal of Manufacturing Systems","volume":"4 1","pages":"pbad022"},"PeriodicalIF":12.2000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680133/pdf/","citationCount":"0","resultStr":"{\"title\":\"Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.\",\"authors\":\"Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang\",\"doi\":\"10.1093/pcmedi/pbad022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).</p><p><strong>Methods: </strong>This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (<i>n</i> = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (<i>n</i> = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.</p><p><strong>Results: </strong>The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were associated with prior exposure to anti-tumor necrosis factor agents and vedolizumab. Furthermore, the fecal lactoferrin trajectory was the most valuable predictor of endoscopic, clinical, and histological remission. Compared to the high/moderate-rapid decrease trajectory group, the moderate-slow decrease, high-slow decrease, and high-stable groups had adjusted odds ratios (95% confidence interval) of 0.38 (0.18, 0.78; <i>P </i>= 0.010), 0.47 (0.23, 0.93; <i>P </i>= 0.032), and 0.33 (0.17, 0.63; <i>P</i> = 0.001), respectively, of 1-year endoscopic remission. Patients with high/moderate-rapid decrease trajectories also had the highest likelihood of achieving clinical and histological remission. Finally, we developed a patient-stratification scheme based on fecal lactoferrin trajectories and concentrations. Patients with good, moderate, and poor prognoses in the scheme had a distinct probability of achieving 1-year endoscopic remission (52.7%, 30.9%, and 12.8%, respectively).</p><p><strong>Conclusions: </strong>The trajectory of fecal lactoferrin is a valuable prognostic factor for 1-year remission in UC.</p>\",\"PeriodicalId\":16227,\"journal\":{\"name\":\"Journal of Manufacturing Systems\",\"volume\":\"4 1\",\"pages\":\"pbad022\"},\"PeriodicalIF\":12.2000,\"publicationDate\":\"2023-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680133/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Manufacturing Systems\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/pcmedi/pbad022\",\"RegionNum\":1,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, INDUSTRIAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Manufacturing Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/pcmedi/pbad022","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, INDUSTRIAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨溃疡性结肠炎(UC)患者粪便乳铁蛋白轨迹的特点及预后价值。方法:本研究使用来自UNIFI试验(ClinicalTrials.gov, NCT02407236)的数据,包括在诱导期间接受ustekinumab的患者进行轨迹建模(n = 637)。在维持治疗期间接受ustekinumab治疗的患者用于1年结局分析(n = 403)。在第0、2、4和8周测定粪便乳铁蛋白、粪便钙保护蛋白和血清c反应蛋白的水平。使用潜在类生长混合模型开发了这些生物标志物的轨迹。结果:粪便乳铁蛋白、粪便钙保护蛋白和血清c反应蛋白的轨迹是不同的,但都与先前暴露于抗肿瘤坏死因子药物和维多单抗有关。此外,粪便乳铁蛋白轨迹是内镜、临床和组织学缓解的最有价值的预测指标。与高/中速下降轨迹组相比,中慢下降、高慢下降和高稳定组的校正优势比(95%可信区间)为0.38 (0.18,0.78;P = 0.010), 0.47 (0.23, 0.93;P = 0.032), 0.33 (0.17, 0.63;P = 0.001),分别为1年的内镜缓解。具有高/中速下降轨迹的患者也有最高的可能性实现临床和组织学缓解。最后,我们根据粪便乳铁蛋白轨迹和浓度制定了患者分层方案。在该方案中,预后良好、中等和较差的患者实现1年内镜缓解的概率明显(分别为52.7%、30.9%和12.8%)。结论:粪乳铁蛋白的轨迹是UC患者1年缓解的一个有价值的预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis.

Objectives: To investigate the characteristics and prognostic value of fecal lactoferrin trajectories in ulcerative colitis (UC).

Methods: This study used data from the UNIFI trial (ClinicalTrials.gov, NCT02407236) and included patients who received ustekinumab during induction for trajectory modeling (n = 637). Patients who received ustekinumab during maintenance therapy were used for 1-year outcome analyses (n = 403). The levels of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were measured at weeks 0, 2, 4, and 8. The trajectories of these biomarkers were developed using a latent class growth mixed model.

Results: The trajectories of fecal lactoferrin, fecal calprotectin, and serum C-reactive protein were distinct, but all were associated with prior exposure to anti-tumor necrosis factor agents and vedolizumab. Furthermore, the fecal lactoferrin trajectory was the most valuable predictor of endoscopic, clinical, and histological remission. Compared to the high/moderate-rapid decrease trajectory group, the moderate-slow decrease, high-slow decrease, and high-stable groups had adjusted odds ratios (95% confidence interval) of 0.38 (0.18, 0.78; = 0.010), 0.47 (0.23, 0.93; = 0.032), and 0.33 (0.17, 0.63; P = 0.001), respectively, of 1-year endoscopic remission. Patients with high/moderate-rapid decrease trajectories also had the highest likelihood of achieving clinical and histological remission. Finally, we developed a patient-stratification scheme based on fecal lactoferrin trajectories and concentrations. Patients with good, moderate, and poor prognoses in the scheme had a distinct probability of achieving 1-year endoscopic remission (52.7%, 30.9%, and 12.8%, respectively).

Conclusions: The trajectory of fecal lactoferrin is a valuable prognostic factor for 1-year remission in UC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Manufacturing Systems
Journal of Manufacturing Systems 工程技术-工程:工业
CiteScore
23.30
自引率
13.20%
发文量
216
审稿时长
25 days
期刊介绍: The Journal of Manufacturing Systems is dedicated to showcasing cutting-edge fundamental and applied research in manufacturing at the systems level. Encompassing products, equipment, people, information, control, and support functions, manufacturing systems play a pivotal role in the economical and competitive development, production, delivery, and total lifecycle of products, meeting market and societal needs. With a commitment to publishing archival scholarly literature, the journal strives to advance the state of the art in manufacturing systems and foster innovation in crafting efficient, robust, and sustainable manufacturing systems. The focus extends from equipment-level considerations to the broader scope of the extended enterprise. The Journal welcomes research addressing challenges across various scales, including nano, micro, and macro-scale manufacturing, and spanning diverse sectors such as aerospace, automotive, energy, and medical device manufacturing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信